Nyxoah S.A (NYXH) | News Based Sentiment Analysis

• On September 9th and 10th, Nyxoah actively engaged with investors at the Morgan Stanley 23rd Annual Global Healthcare Conference and Baird's 2025 Global Healthcare Conference in New York, NY, presenting updates and holding one-on-one meetings – a key step in building momentum following the recent FDA approval of the Genio system.
• Six analysts maintained a "Buy" consensus rating for Nyxoah as of September 13, 2025, with 33% recommending a "Strong Buy," 50% a "Buy," and 17% a "Hold," signaling continued confidence in the company’s prospects. The price target remained steady at $16.50.
• Nyxoah demonstrated significant financial improvement in Q2 2025, achieving a gross margin of 73%, a substantial increase from 62% in the prior quarter, indicating improved operational efficiency and pricing power.
• Cochlear Investments Pty Ltd slightly decreased its holding in Nyxoah to 14.999% of total voting rights (5,631,319 voting rights) as of August 29, 2025, a passive crossing of a threshold that, while not immediately concerning, warrants investor attention.
• Analysts set an average target price of $12.77 for Nyxoah as of September 11, 2025, representing a potential upside of 129.33%, based on four "Buy" ratings and one "Hold" rating, though the company currently has a negative forward P/E ratio of -2.92 and an EPS of -2.49.
• On September 9, 2025, Nyxoah’s stock closed at €4.97 on Euronext, reflecting market activity during a period of increased investor engagement and positive analyst coverage.

The Investment Story: September was a month of proactive investor engagement for Nyxoah, building on the momentum of the Genio system’s FDA approval. Positive analyst sentiment and improved gross margins were offset by a minor reduction in Cochlear’s stake.

What It Means for Investors: The continued “Buy” ratings and improved financial performance suggest confidence in Nyxoah’s long-term potential. However, investors should monitor the slight change in Cochlear’s shareholding and the company’s path to profitability, given its current negative P/E ratio.

Looking Ahead: Investors should closely monitor the impact of the investor conferences and track the Genio system’s commercial rollout. Continued attention to cash burn and any further changes in major shareholdings will also be crucial.

The Bottom Line: Nyxoah remains a high-risk, high-reward investment. The FDA approval is a significant milestone, and the company is actively working to capitalize on it. Successful commercialization of the Genio system will be key to unlocking its potential, but investors should be prepared for continued volatility.